Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott/TheraSense FDA panel rescheduled

This article was originally published in The Gray Sheet

Executive Summary

Diabetes test manufacturer is working with FDA to establish a panel date for the FreeStyle Navigator continuous glucose monitor system, which uses interstitial fluid, after the agency mistakenly issued and then retracted a notice that its Clinical Chemistry & Clinical Toxicology Devices Panel would review the device on Oct. 13. TheraSense submitted a PMA last November. Upon approval, FreeStyle will compete with Medtronic's Guardian CGMS. Roche/Disetronic is developing similar technology...

You may also be interested in...



Glucon Preps For 2005 Clinical Trial Of Continuous Blood Sugar Monitor

Clinical trials on the sensitivity and specificity of Glucon's continuous glucose monitor will begin in Q3 2005, according to Benny Pesach, PhD, founder and VP-research & development

US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived

Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.

E.l.f. Has A Go At Twitch Crowd, Hitching Wagon To #Loserfruit

The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel